Your browser doesn't support javascript.
loading
Recurrence Pattern, Treatment Modalities, and Prognostic Factors After Definitive Chemoradiotherapy for Recurrent Esophageal Cancer.
Akahane, Keiko; Hatanaka, Shogo; Kawahara, Masahiro; Endo, Masashi; Fukuda, Yukiko; Okada, Kohei; Ogawa, Kazunari; Takahashi, Satoru; Nakamura, Michiko; Saito, Masaaki; Oyama-Manabe, Noriko; Shirai, Katsuyuki.
Afiliación
  • Akahane K; Department of Radiology, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
  • Hatanaka S; Department of Radiation Oncology, Ageo Central General Hospital, Saitama, Japan.
  • Kawahara M; Department of Radiology, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
  • Endo M; Department of Radiology, Jichi Medical University, Tochigi, Japan.
  • Fukuda Y; Department of Radiology, Jichi Medical University, Tochigi, Japan.
  • Okada K; Department of Radiology, Jichi Medical University, Tochigi, Japan.
  • Ogawa K; Department of Radiology, Jichi Medical University, Tochigi, Japan.
  • Takahashi S; Department of Radiology, Jichi Medical University, Tochigi, Japan.
  • Nakamura M; Department of Radiology, Jichi Medical University, Tochigi, Japan.
  • Saito M; Department of Surgery, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Oyama-Manabe N; Department of Radiology, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
  • Shirai K; Department of Radiology, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan. kshirai@jichi.ac.jp.
J Gastrointest Cancer ; 55(2): 809-819, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38280175
ABSTRACT

BACKGROUND:

Recurrent esophageal cancer (EC) has a poor prognosis. However, the recurrence patterns and therapeutic outcomes after definitive chemoradiotherapy (CRT) are not fully understood. We analyzed survival and prognostic factors associated with post-definitive CRT recurrent EC.

METHODS:

We retrospectively reviewed 71 consecutive patients with post-definitive CRT EC recurrence between 2008 and 2021 at our institution. Recurrence was locoregional, distant, and combined in 42 (59%), 18 (25%), and 11 (16%) patients, respectively. The median time from definitive CRT to recurrence was 8.3 months. Treatment modalities included local therapy, systemic therapy, and palliative care. Overall survival (OS) after recurrence was analyzed using the Kaplan-Meier and Cox proportional hazards models.

RESULTS:

The median follow-up time from recurrence was 7.1 months, and the median survival time (MST) was 12.5 months. In the univariate analysis, longer time to recurrence, earlier stage at initial treatment, surgical tolerance at initial diagnosis, treatment modalities, and oligo-recurrence were associated with a better prognosis. The MST of the local therapy, systemic therapy, and palliative care groups were not reached, 11.8 months and 4.1 months, respectively (P < 0.001). In the multivariate analysis, treatment modalities and oligo-recurrence emerged as independent prognostic factors (P < 0.001 and P = 0.009).

CONCLUSIONS:

Aggressive local therapy should be considered to improve the prognosis for patients with oligo-recurrence and/or indication of local therapy to treat recurrent EC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Quimioradioterapia / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Cancer Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Quimioradioterapia / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Cancer Año: 2024 Tipo del documento: Article País de afiliación: Japón